Pyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles.
about
Potentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel HydroxypyrazolinesIdentification of inhibitors against interaction between pro-inflammatory sPLA2-IIA protein and integrin αvβ3.ΔF508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles.Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTRF508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.Functional fluorescently labeled bithiazole ΔF508-CFTR corrector imaged in whole body slices in mice.Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in ΔF508 cystic fibrosis transmembrane conductance regulator proteinClick-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.CFTR: folding, misfolding and correcting the ΔF508 conformational defect.Cystic fibrosis transmembrane regulator correctors and potentiators.Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator.The search for a common structural moiety among selected pharmacological correctors of the mutant CFTR chloride channel.Recovery of ΔF508-CFTR function by analogs of hyaluronan disaccharide.Molecular basis of cystic fibrosis: from bench to bedside
P2860
Q28550065-05126A6E-8DC9-43B5-B8EC-C684AAA8B259Q34481371-13DE020D-2C0C-468C-8A0B-A7867BC7F822Q34628552-7A0DB2C3-F178-4A81-89F3-523C8090420DQ35275305-E0A457C7-0E31-44C4-ACC5-87FCC110F45FQ35275697-AB145B71-756D-48CC-8A82-F007C3B0EE38Q35630919-5A48684F-90CD-4E22-8E3F-A326FB9F20E3Q35633406-34AA7714-D6B9-441D-BA1F-8653222B77C1Q35750147-52049C37-FAEB-4183-BBE1-AE0964F7093FQ36166335-B4FD80DD-2C60-439C-83DB-CAA708DEDEF6Q36814102-E14E3DD9-EAAC-40D3-A097-6E084A977205Q38118742-0EF245E1-3C6D-48A7-9B1C-90954FD10FD2Q38809280-9BDDCCED-0F1C-4E9A-BECD-0F97A03C8AFFQ39077956-1DE4BA3F-9CD7-49CA-9773-D9E04FC00ADCQ39481242-11B9A831-2BD0-45C1-8655-7E0674832CF7Q57300566-878CA1D8-820D-422C-86AB-CF64A2C32540
P2860
Pyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pyrazolylthiazole as DeltaF508 ...... icity compared to bithiazoles.
@ast
Pyrazolylthiazole as DeltaF508 ...... icity compared to bithiazoles.
@en
Pyrazolylthiazole as DeltaF508 ...... icity compared to bithiazoles.
@nl
type
label
Pyrazolylthiazole as DeltaF508 ...... icity compared to bithiazoles.
@ast
Pyrazolylthiazole as DeltaF508 ...... icity compared to bithiazoles.
@en
Pyrazolylthiazole as DeltaF508 ...... icity compared to bithiazoles.
@nl
prefLabel
Pyrazolylthiazole as DeltaF508 ...... icity compared to bithiazoles.
@ast
Pyrazolylthiazole as DeltaF508 ...... icity compared to bithiazoles.
@en
Pyrazolylthiazole as DeltaF508 ...... icity compared to bithiazoles.
@nl
P2093
P2860
P356
P1476
Pyrazolylthiazole as DeltaF508 ...... icity compared to bithiazoles.
@en
P2093
A S Verkman
John M Knapp
Mark J Kurth
Panjamaporn Sangwung
P2860
P304
P356
10.1021/JM100235H
P407
P577
2010-05-01T00:00:00Z